Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Chimeric Antigen Receptor T Cells (CAR-T)
100%
T Cells
32%
Chimeric Antigen Receptor T-cell Therapy
28%
T Cell Depletion
23%
Adoptive Cell Therapy
16%
T Cell Activation
16%
CD19
16%
B-cell Malignancies
15%
T Cell Targeting
14%
Cell Therapy
13%
Acute Lymphoblastic Leukemia
12%
Chimeric Antigen Receptor Therapy
12%
Clinical Trials
12%
Engineered T Cells
11%
Neuroblastoma
10%
Genome Editing
10%
Resistance Mechanisms
10%
Tumor
9%
4-1BB
9%
Co-stimulatory Domain
8%
CD22
8%
Adoptive Immunotherapy
8%
Xenograft Model
8%
Antigen-independent
8%
Highly Active
8%
Leukemia
7%
Cancer Immunotherapy
7%
Hematological Malignancies
6%
CART19
6%
Solid Tumors
6%
Autologous T Cell
6%
Culture Method
6%
Ovarian Cancer
6%
Chronic Lymphocytic Leukemia
6%
Pediatric Malignancy
6%
Non-Hodgkin Lymphoma
6%
Early Memories
5%
Memory Phenotype
5%
Hematopoietic Cell Transplantation
5%
B-cell Lymphoma
5%
Medicine and Dentistry
T Cell
61%
Chimeric Antigen Receptor T-Cell
54%
Chimeric Antigen Receptor
34%
Chimeric Antigen Receptor T-Cell Immunotherapy
22%
Neoplasm
21%
Cell Therapy
21%
Immunotherapy
20%
Cancer
20%
Diseases
19%
Chimeric Antigen Receptor Immunotherapy
17%
B Cell
15%
Ganglioneuroblastoma
14%
Malignant Neoplasm
13%
Acute Lymphoblastic Leukemia
12%
Genome Editing
10%
Clinical Trial
9%
B-Cell Lymphoma
8%
B-Cell Chronic Lymphocytic Leukemia
7%
Solid Malignant Neoplasm
6%
Pediatrics
6%
Childhood Cancer
6%
Infusion
6%
Cytotoxicity
5%
Hematologic Malignancy
5%
Leukemia
5%
Cell Transplantation
5%
Hematopoietic Cell
5%
Immunocompetent Cell
5%
Cell Function
5%
Immunology and Microbiology
T Cell
46%
Chimeric Antigen Receptor T-Cell
38%
Chimeric Antigen Receptor
37%
Immunotherapy
20%
Cell Function
10%
CD19
10%
B Cell
8%
CD22
8%
Chimeric Antigen Receptor T-Cell Therapy
7%
Peptides
7%
Cytotoxicity
5%
Antigen Specificity
5%